| 000 | 01745 a2200529 4500 | ||
|---|---|---|---|
| 005 | 20250516004725.0 | ||
| 264 | 0 | _c20101124 | |
| 008 | 201011s 0 0 eng d | ||
| 022 | _a1527-3350 | ||
| 024 | 7 |
_a10.1002/hep.23892 _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aSharma, Dipali | |
| 245 | 0 | 0 |
_aAdiponectin antagonizes the oncogenic actions of leptin in hepatocellular carcinogenesis. _h[electronic resource] |
| 260 |
_bHepatology (Baltimore, Md.) _cNov 2010 |
||
| 300 |
_a1713-22 p. _bdigital |
||
| 500 | _aPublication Type: Journal Article; Research Support, N.I.H., Extramural | ||
| 650 | 0 | 4 |
_aAdiponectin _xtherapeutic use |
| 650 | 0 | 4 | _aAnimals |
| 650 | 0 | 4 |
_aApoptosis _xdrug effects |
| 650 | 0 | 4 |
_aCarcinoma, Hepatocellular _xepidemiology |
| 650 | 0 | 4 |
_aCell Division _xdrug effects |
| 650 | 0 | 4 | _aCell Line, Tumor |
| 650 | 0 | 4 | _aCell Movement |
| 650 | 0 | 4 |
_aDNA, Neoplasm _xanalysis |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 | _aImmunohistochemistry |
| 650 | 0 | 4 | _aIn Situ Nick-End Labeling |
| 650 | 0 | 4 |
_aLeptin _xantagonists & inhibitors |
| 650 | 0 | 4 |
_aLiver Neoplasms _xepidemiology |
| 650 | 0 | 4 | _aMice |
| 650 | 0 | 4 | _aMice, Nude |
| 650 | 0 | 4 |
_aObesity _xcomplications |
| 650 | 0 | 4 | _aPhosphorylation |
| 650 | 0 | 4 | _aTransplantation, Heterologous |
| 700 | 1 | _aWang, Jason | |
| 700 | 1 | _aFu, Ping P | |
| 700 | 1 | _aSharma, Shvetank | |
| 700 | 1 | _aNagalingam, Arumugam | |
| 700 | 1 | _aMells, Jamie | |
| 700 | 1 | _aHandy, Jeffrey | |
| 700 | 1 | _aPage, Andrew J | |
| 700 | 1 | _aCohen, Cynthia | |
| 700 | 1 | _aAnania, Frank A | |
| 700 | 1 | _aSaxena, Neeraj K | |
| 773 | 0 |
_tHepatology (Baltimore, Md.) _gvol. 52 _gno. 5 _gp. 1713-22 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1002/hep.23892 _zAvailable from publisher's website |
| 999 |
_c20245534 _d20245534 |
||